A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.

Trial Profile

A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Atesidorsen (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Nov 2015 Results from secondary efficacy analysis will be presented at the Society for Endocrinology BES 2015 conference, according to a Strongbridge Biopharma media release.
    • 08 Mar 2015 Updated results presented at The 97th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top